Astellas builds its R&D footprint in Cambridge/Boston with an add-on for labs, offices
Astellas is snapping in another piece of the real estate puzzle for its global R&D reorganization.
Just as it wraps one project to piece together its parts in the Bay Area, the Japanese pharma player has found a new home for a slate of groups operating in the all-important Cambridge/Boston hub.
Astellas signed up for two floors of the 375,000-square-foot 441 Morgan Avenue development, a big project by DivcoWest, with plans to cut the ribbon on new lab and office space in the middle of next year. The 10-story building is part of Cambridge Crossing, the sprawling 43-acre development sited at the joining of Cambridge, Somerville, and Boston.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.